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AIDS AS A CHRONIC ILLNESS: A CAUTIONARY TALE
FOR THE END OF THE TWENTIETH CENTURY
Linda C.Fentiman*

Forecasting is always a risky business, particularly a t the beginning of the year. Nonetheless I predict that 1998 will be the year
that AIDS becomes a mainstream disease, no more likely to receive
special legal solicitude or extra government funding than other
chronic diseases which afflict a wide spectrum of American society.
AIDS is ready to come of age and lose its status as a specialty disease, due to the confluence of four major phenomena. These are:
(1)significant clinical innovations in AIDS treatment,l(2) a shift in
the demographics of persons living with AIDS and HIV,2 (3) a reconfigured and refinanced health care delivery system,3 and (4) new
legal thinking about people with disabilities.4 Some AIDS advo* Professor of Law and Director, Health Law and Policy Program, Pace University School
of Law. B.S., Cornell University, 1970; J.D., State University of New York at Buffalo Law
School, 1975; LL.M., Harvard University School of Law, 1983. The author gratefully acknowledges the advice and counsel of Professor Joshua Greenberg and the invaluable research assistance of Marleen Kelley, Pace University School of Law, Class of 1999.
1 See Deborah Sontag & Lynda Richardson, Doctors Withhold H.I.V. Pill Regimen fiom
Some, N.Y. TIMES,Mar. 2, 1997, at A1 (discussing protease inhibitors as an AIDS treatment
that will prolong patients' lives).
a See David Brown, Poverty Entangles Promise of Powerful Treatment, WASH.POST,Sept.
1,1997, at A1 (reporting an increase in the number of African-Americans, women, and intravenous drug users living with HIV and AIDS rather than gay white men who made up a
majority of the AIDS sufferers in the 1980s);Minorities Miss Out on AlDS Survival Increase,
AIDS ALERT, May 1, 1997, available in 1997 WL 8961938 (noting that African-Americans
have AIDS at seven times the rate of whites, and Hispanics have AIDS at three times the
white rate).
3 See RAND E. ROSENBLA~
ET AL., LAW AND THE AMERICAN HEALTH CARESYSTEM12
(1997); Eleanor D. Kinney, Medicare Managed Care from the Beneficiary's Perspective, 26
SETONHALL L. REV. 1163, 1163 (1996) (stating that "managed care is fast becoming the predominant model for the delivery of health care services in the United States"); see also Her& GAZETIX(Worcester, Mass.), Sept. 29, 1997, at A7
bert M. Dean, As I See it, TELEGRAM
(discussing the high rates of growth in Health Maintenance Organization [hereinafter HMO]
programs and managed care).
4 See Arti Kaur Rai, Rationing Through Choice: A New Approach to Cost-Effectiveness
Analysis in Health Care, 72 IND. L.J. 1015, 1016-19 (1997) (arguing for cost-effectiveness in

Heinonline - - 61 Alb. L. Rev. 989 1997-1998

990

Albany Law Review

[Vol. 63

cates themselves are beginning to reassess the desirability of "AIDS
exceptionalism," the notion that because the diagnosis of HIV is
both clinically devastating and socially stigmatizing, HIV and AIDS
require special status and special resources.6 In addition, public
health specialists and some AIDS advocacy groups, including the
Gay Men's Health Crisis in New York, support the idea of mandatory reporting of HIV test results to state health departments.6
Mandatory reporting permits the collection of more accurate epidemiological data on the incidence of HIV infection, as well as
AIDS, now that HIV infection itself is recognized as a chronic
health condition necessitating medical intervention.7 This new
openness to data collection reflects a growing consensus that HIV
and AIDS are less stigmatizing than they once were, as more and
more Americans' lives are touched by the disease. At the same
time, the urgent need for more accurate information for formulating
public health policy is seen by some to outweigh the infringement of
individual privacy rights and the potential deterrent effect on those
seeking HIV and AIDS treatment that have traditionally been
grounds for opposing mandatory HIV reporting, particularly if
names are attached to positive test results.8
In examining the demise of AIDS as sui generis, it is necessary to
understand the impact of converging medical, financial, and sociopolitical forces over the last fifteen years. During that time AIDS
has evolved from a swiftly fatal illness whose etiology was unknown, to a well-studied, treatable chronic disease where death can
frequently be staved off for a lengthy time, although not forestalled
altogether.9 AIDS is thus similar to many other chronic diseases
rationing health care); Chris Watkins, Comment, Beyond Status: The Americans with Disabilities Act and the Parental Rights of People Labeled Developmentally Disabled or Mentally
Retarded, 83 CAL.L. REV.1415, 1430 (1995) (noting that one aim of the Americans with Disabilities Act [hereinafter ADA] is to change legal thinking about people with disabilities).
6 See Sheryl Gay Stolberg, New Challenge to Idea that "AIDS is Special," N.Y. TIMES, Nov.
12,1997, at A1 (emphasizing that AIDS is a special disease that requires a special response).
6 See, e.g., Michael Lasalandra, Health Offiials May Require Doctors To Report All H W
Patients in State, BOSTONHERALD,
Jan. 14,1998, at 15.
7 See Lynda Richardson, AIDS Group Urges New York To Start Reporting of H.Z.V., N.Y.
TIMES,
Jan. 13, 1998, at A1 (noting the importance of states requiring doctors to report AIDS
cases to public officials).
8 See First-ever AIDS Incidence Decline Marks Start of a New Era in Epidemic, AIDS
ALERT, Nov. 1, 1997, available in 1997 WL 8961981 (stating that improving the ability to
monitor HIV infection is essential to determine patterns of the AIDS epidemic and to finding
cures).
9 See Deborah J. Cotton, Improving Survival in Acquired Immunodeficiency Syndrome: Is
Experience Everything?, 261 JAMA 3016, 3016 (1989) (discussing the progress in treatment
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for which a remarkable series of genetic, medical, and pharmaceutical advances now hold out the potential for control, if not cure.10
With AIDS, substantial treatment breakthroughs have occurred
in the year and a half since the 1996 International Conference on
AIDS in Vancouver.11 Thousands of HIV-positive and AIDS patients across the United States have embarked upon new treatment
regimens, taking protease inhibitors daily along with other drugs.12
In many cases, these individuals have experienced significant remission in their disease.13 These new "cocktails" are so successful
for many people that in 1996, for the first time since the AIDS epidemic began, the number of deaths nationwide due to AIDS fell
compared to the year before.14 The trend has continued in 1997,
with data from New York City showing that the death toll from
AIDS decreased by forty-eight percent.15
Dramatic clinical breakthroughs have also changed the standard
of care and quality of life for other chronic disease sufferers. The
nicotine patch has helped smokers withdraw from their tobacco addiction, thus halting the onslaught of emphysema, cancer, and cardiovascular disease.16 Psychotropic drugs have shortened hospital
for AIDS). Advances in AIDS treatment helps persons primarily in the Western developed
world who have access to expensive, innovative treatment, and who are lucky enough to respond well to it. This Article limits its observations to the United States.
10 See David Brown, "Triple Therapy" Doesn't Destroy H N , WASH.POST,Nov. 14, 1997, at
A4 (noting that while progress is slow, and final results are speculative, new drug breakthroughs can help to control HIV infection).
11 See AIDS Deaths Fall Sharply; New Treatments Credited, WASH.POST,Feb. 3, 1998, at
A2 (attributing the decline in AIDS deaths in 1997 to treatment breakthroughs); David
Brown, With Fanfare, Global AIDS Conference Gets Underway in Vancouver, WASH.POST,
July 8, 1996, a t A4 (reporting the opening of the eleventh International Conference on AIDS).
12 Protease inhibitors work by interfering with the HIV virus's ability to copy itself, thus
limiting its spread within the body. See Thomas H. Maugh 11, Hopes Rise for Inexpensive
AIDS Drug, L.A. TIMES, Feb. 6,1998, at Al.
13 See Lawrence K. Altman, AIDS Deaths Drop 48% in New York, N.Y. TIMES, Feb. 3,
1998, at A1 (analyzing data to show the progress of new AIDS treatments).
14 See Centers for Disease Control and Prevention, Update: Trends in AIDS ZncidenceUnited States, 1996,46 MORBIDITY
& MORTALITY
WKLY.REP.861,861 (1996) (noting the decline in AIDS deaths in 1996).
16 See Altman, supra note 13, at Al.
16 See Matthew Baldini, The Cigarette Battle: Anti-Smoking Proponents Go for the KnockL. REV.348,370 (1995)(stating that lung cancer was the most prevalent
out, 26 SETONHALL
cancer linked to smoking, and noting other smoking related diseases such as chronic bronchitis, emphysema, and coronary artery disease); J. Michael McGinnis & William H. Foege, Actual Causes of Death in the United States, 270 JAMA 2207, 2208-10 (1993) (finding that tobacco ranks as one of the leading causes of death among Americans); Christina Del Valle,
Want to Stop Smoking? There Are More Ways than Ever To Quit, NEWSDAY,
Jan. 19, 1998, at
B13 (observing the availability of nicotine patches, gums, sprays, and inhalers to help smokers quit).
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stays and liberated many mentally ill people from debilitating depression, schizophrenia, and bipolar disorders.l7 Similarly, pancreatic transplants (including the Islets of Langerhans, the source of
insulin) are poised to radically alter the treatment of diabetes.ls
During this same time period the landscape of American health
care has changed dramatically. In the early 1980s, health care in
the United States was largely provided within a fee-for-service system, in which eighty percent of Americans under age sixty-five had
private health insurance, primarily through employment, with relatively comprehensive coverage.19 Today, managed care is the predominant form of health care delivery in the United States.20 Managed care relies on new organizational delivery structures, both
corporate and contractual, utilization review processes, and financial incentives to provide less care, in order to contain costs and to
avoid medically unnecessary and potentially dangerous treatment.21
At the same time, slightly more than half of all Americans receive
health care coverage through an employer who is self-insured.22
Because of the Employee Retirement Income Security Act of 197423
(ERISA) preemption by these employee benefit health plans are not
17

See Lou Chapman, Fear of Mentally Ill Called Sign of Ignorance, FORT WORTHSTAR-

TELEGRAM,
Apr. 11, 1997, at 2 (stating that drugs reduce the need for hospitalization and
counseling, and that 60% to 80% of bipolar disorders can be treated with drugs); Deborah
Kelly, Medicating the Mind: Breakthrough Drugs May Hold Promise for Many, RICHMOND
TIMES-DISPATCH,
Dec. 11, 1997, at E l (stating that new antipsychotic medications have been
called miracle drugs for persons with schizophrenia and manic-depression).
18 See Kathleen Doheny, Body Watch Zeroing in on Diabetes, L.A. TIMES,
May 28, 1997, at
E2 (discussing one transplantee's foray into pancreas transplantation);David N. Leff, French
Diabetologists Couple Cholera Toxin to Insulin as Diabetes Type 1 Vaccine, BIOWORLD
TODAY,
May 6 , 1997, available in 1997 W L 7473764 (stating that pancreas transplants can be a successful cure for diabetes);John G. Leyden, A Good Idea and a Lot of Sweat Led to Diabetes
POST, Apr. 22,
Treatment; Insulin Developed by Team Effort Without Team Spirit, WASH.
1997, at Z18 (discussing the discovery of the Islets of Langerhans, the small microscopic cell
clusters which produce insulin).
19 See ROSENBLA~T
ET AL., supra note 3, at 12 (discussing the structure of the health care
delivery system).
20 See Kinney, supra note 3, at 1163 (stating that both public and private payers are
seeking to control the escalating costs of health care); see also Dean, supra note 3, at A7
(noting that over 70% of employer sponsored health care is i n some form of managed care).
21 See Diana Joseph Bearden & Bryan J. Maedgen, Emerging Theories of Liability in the
Managed Health Care Industry, 47 BAYLORL. REV. 285, 288-89 (1995)(discussing the methods managed care organizations use to evaluate patient care);Elaine Lu, The Potential Effect
of Managed Competition in Health Care on Provider Liability and Patient Autonomy, 30
HARV. J. ON LEGIS.519,521-28 (1993)(same).
22 See Alex Pham, Aetna To Halt Some Infertility Coverage: Thousands To Be m e c t e d in
Mass., BOSTONGLOBE,Jan. 10, 1998, at F1 ("Approximately half of the nation's insured
population belong to self-insured plans, according to insurance experts.").
23 29 U.S.C.$3 1001-1461 (1994).
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governed by state laws providing relief when insurance coverage is
"unfairly" denied,24 thus leaving many employees and their families
remediless when a plan will not cover arguable medically necessary
care.
Federal efforts to protect people from the most Draconian aspects
of health insurance have met with limited success, and are largely
incremental in nature. They include the Health Insurance Portability and Accountability Act of 1996 (HIPAA),25 which was designed to limit the impact of preexisting conditions on access to insurance, and the Mental Health Parity Act of 1996,26 .which
requires that when employee benefit plans offer coverage for both
physical and mental illnesses, the total dollar value of the coverage
must be the same, unless the employer demonstrates financial
hardship.27 There are millions of Americans who are either forced
to stay in a job they don't want solely because of its health insurance coverage or who lack access to needed medical services because they happen to have the wrong disease. Nearly forty-two
million Americans lack any health care insurance, even the government financed insurances of Medicare and Medicaid.28 In New
York City, twenty percent of the population under age 65 is uninsured.29
The result of these monumental shifts in the structure and financing of health care delivery is that a t the very time that medical
innovations have made possible significant improvements in the
quality and quantity of life for people with chronic illnesses, those
who are responsible for paying for Americans' health care, in government and the private sector, seem to have finally said "Enough!
We must cut costs, and cut them dramatically, and the simplest,
most direct way of cutting costs is to deny coverage for certain
kinds of treatments and certain kinds of illnesses." People with HIV
and AIDS are among those who are struggling, often unsuccessfully, for access to medically necessary treatment, but they are no
24 See Michael T. Isbell, AIDS and Access to Care: Lessons for Health Care Reformers, 3
CORNELL J.L. & PUB. POL'Y 7,21(1993).
26 Pub. L. No. 104-191,110 Stat. 1936 (1996).
26 42 U.S.C. 8 3OOgg-5 (1994).
27 See id.
28 See PAUL~ N S T I N ,SOURCES
OF HEALTH
INSURANCE AND CHARACTERISTICS OF THE
UNINSURED2 (Employee Benefit Research Institute Issue Brief No. 192, 1997)
(demonstrating that 41.4 million non-elderlyAmericans have no health care insurance).
29 See Ian Fisher, Even as Economy Booms, More People Are Going Without Insurance,
N.Y. TIMES,Feb. 12, 1998, at B1 (noting that the number of people without medical insurance is rising far faster in New York State than in the rest of the country).
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longer alone. Millions of other Americans living with chronic disease face similar problems as they seek medical treatment that is
effective, multi-faceted, and expensive in a health care system increasingly bent on controlling both the costs the structures of
health care delivery. We thus stand a t the threshold of a critical
question: What lessons does the AIDS pandemic provide for American health care in general?

It is always cheaper to prevent illness than to treat

AIDS,
along with many other illnesses linked to human behavior, exemplifies the limitations of American public health policy as it is directed
a t chronic disease reduction. Government and private payers spend
very little on cost-effective preventive public health strategies.31
State health departments spend only three percent of their budgets
on prevention and less than one percent of government funding
supports public health initiatives.32 Although approximately $425
billion was spent in 1994 to treat the six major chronic diseases
(heart disease, cancer, stroke, diabetes, chronic obstructive pulmonary disease, and chronic liver disease), less than one percent of
it.30

30 See Stephenie Overman, Managed Care Companies Still Emphasize Prevention, L.A.
BUS. J., Sept. 22, 1997,available in 1997 WL 9559235 (noting that some HMOs are starting
to place more emphasis on prevention); Thomas J. Prohaska, Health Leader Backs Needle
Exhange, BUFF.NEWS, Sept. 28, 1997, a t C1 (arguing that focusing on the prevention of
HIV/AIDS is cost effective).
31 Indeed, the publicity which has attended the successful clinical and pharmaceutical innovations in AIDS treatment in the United States and other Western countries has obscured
the growing AIDS pandemic in the rest of the world, where drug therapies are far too expensive to be useful to more than a handful of those infected with HIV. Western AIDS research
efforts, both publicly and privately funded, have concentrated on treatment breakthroughs,
while for other countries, the only hope for limiting the spread of the disease is in prevention,
through education about high risk behaviors, and the development and use of a n AIDS vaccine. See Andrew Purvis, The Global Epidemic, TIME, Dec. 30, 1996,a t 76-78(describing recent AIDS prevention programs in African countries). In the United States Phase I11 clinical
trials are about to begin for a n AIDS virus drug. See AIDS Vaccine Approved for Human
POST, Jan. 12, 1998, a t All (reporting that the first AIDS vaccine has been
Trials, WASH.
approved by the Food and Drug Administration to move to "phase I11 testing"). A recent
United Nations report estimated that there are 16,000new cases of HIV infection each day.
See Robert Pear, New U.N. Estimate Doubles Rate of Spread of AIDS Virus, N.Y. TIMES, Nov.
26,1997,a t A3.
32. See Medical Costs To Surge for Chronic Disease Treatment, MED. INDUS.
TODAY,
Apr. 7,
1997,available in LEXIS, News Library, Medtdy File; see also Edward L. Baker e t al., Health
Reform a n d the Health of the Public: Forging Community Health Partnerships, 272 JAMA
1276,1277 (1994) (stating there has been a n "erosion of core public health finding).
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that amount ($287 million) was spent on prevention efforts.33 Many
health care insurers and other payers do not pay for preventive
health care (well-baby check-ups, mammographies, etc.), although
this may change as managed care, which has marketed preventive
care as one of its hallmarks, gains greater prevalence in American
health care delivery.34 In 1993, Drs. Michael McGinnis and William
Foege estimated that approximately one half of all deaths in the
United States could be forestalled by prophylactic health care
measures, including changes in sexual and driving behavior, food
and alcohol consumption, and the use of tobacco and other drugs.35
For example, we know that more than forty percent of high school
students, both boys and girls, use cigarettes and other tobacco
products, and that eighty-five percent of current adult smokers began before the age of 18.36 In forty years, many of these students
will become sufferers from cancer, emphysema, and heart disease.
Similarly, McGinnis and Foege suggested that as many as 300,000
deaths annually could be prevented if people decreased their consumption of calories, particularly animal fat, and increased their
level of exercise, thus reducing their risk of developing diabetes and
heart disease.37
With AIDS, four effective prevention strategies have been identified: counseling individuals to change their sexual and other high
risk behaviors, explicit sex education programs, condom distribution, and the provision of clean needles to intravenous drug users.38
Public and private health policymakers have frequently resisted the
implementation of these strategies for moral, fiscal, or political rea-

See Medical Costs To Surge for Chronic Disease Treatment, supra note 32.
See A Managed Care Primer, PEOPLE'SMED. SOC'Y,Oct. 1,1997, at A1 (noting the goals
o f managed care are to provide services to keep people healthy); David Algeo, Managing
Medicaid HMO's New Law Presents Challenges for Health-Maintenance Organizations,
DENVER
POST,June 29,1997, at H1 (stating managed care focuses on prevention of illness).
36 See McGinnis & Foege, supra note 16, at 2211 (linking approximately half o f all deaths
in the United States to identifiable factors).
36 See Sheryl Gay Stolberg, Rise i n Smoking by Young Blacks Erodes a Success Story,
N.Y.TIMES, Apr. 3, 1998, at A24; Professor Richard J. Bonnie, Presentation at the Pace University School o f Law Conference, Tobacco and the Public Health: Social Policy and Legal
Issues (Apr. 19, 1997).
37 See McGinnis & Foege, supra note 16, at 2208 (estimating that 35% o f all cancer deaths
are attributable t o diet).
38 See William N.Eskridge, Jr. & Brian D. Weimer, The Economics Epidemic i n a n AIDS
Perspective, 61 U . CHI.L. REV. 733, 766-70 (1994);Needle Exchange Programs Comprehen. sive Approach Found To Be Best Way To Prevent HIVAmong Drug Users, AIDS WKLY. PLUS,
Sept. 22,1997, at 19, available in 1997 WL 11007268.
33
34
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sons.39 Similar short-sightedness characterizes most states' regulation of hypodermic syringes, as they severely limit access to syringes in order to discourage drug abuse, overlooking the increased
transmission of hepatitis, HIV, and other blood-borne diseases
which inevitably accompanies such restrictive measures.@
Numerous studies demonstrate that an ongoing relationship with
a health care professional is crucial to changing a person's sexual
behavior by influencing the individual to use condoms or to limit
the number of sexual encounters, but this knowledge has not been
effectively implemented due to organizational or political constraints on health care delivery.41 Although many managed care
organizations endeavor to ensure continuity of care, frequently
their patients do not see the same health care provider regularly,
and thus lack the sort of practitioner-patient relationship which can
encourage a change in high risk behavi0r.4~As governments reduce
access to sexually transmitted disease clinics and other reproductive healthcare services, they lose a valuable opportunity to counsel
people about the risks of unprotected sex and intravenous drug
use.43 Unprotected sexual intercourse accounted for more than
30,000 deaths in 1990, including 21,000 from sexually acquired HlV
infections, 4000 from cervical cancer, 1600 from sexually acquired
Hepatitis B infections, and 5000 deaths of infants due to unplanned
pregnancies and a concomitant lack of prenatal care.44 In almost all
states possession of a hypodermic needle or syringe with the intent
to use it to inject drugs is illega1.45 Eight states additionally require
a prescription to purchase a needle or syringe, although several of
the states, including New York, permit syringe possession in con3g See Lawrence 0.Gostin et al., Prevention of HNIAIDS and Other Blood-Borne Diseases Among Injection Drug Users: A National Survey on the Regulation of Syringes and
Needles, 277 JAMA 53,54-55 (1997).
40 See id. at 54 (noting "[dlrug paraphernalia statutes ban the manufacture, sale distribution, possession, or advertising.. . of devices known to be used (or reasonably should be
known to be used) to introduce illicit substances into the body").
41 See, e.g., James G. Kahn, The Cost-Effectiveness of H N Prevention Targeting: How
Much More Bang for the Buck?, 86 AM. J. PUB. HEALTH 1709, 1711 (1996) (suggesting that
HIV prevention services help to stop the spread of HIV and reduce costs).
42 See Isbell, supra note 24, at 27-28.
43 See Jim Yardley, Breaking the H.Z.V. Chain: Clinic Battles Spread of Infection-nd
Jan. 25, 1998, a t K27.
Despair, N.Y. TIMES,
44 See McGinnis & Foege, supra note 16, a t 2210.
45 See Gostin et al., supra note 39, a t 54 ("Forty-seven states, the District of Columbia,
and the Virgin Islands have enacted drug paraphernalia laws; only Alaska, Iowa, South
Carolina, and four territories have no state-or territory-wide drug paraphernalia statute.").
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nection with a state-approved syringe exchange program.46 These
programs have been shown to cut the rates of H N infection substantially.47
Aggressive interventions to reduce the incidence of other chronic
diseases have been proposed, including the Food and Drug Administration's (FDA) regulations banning most advertising of tobacco
products to children under eighteen,* and screening of high risk
groups for diabetes.49 Other preventive public health measures,
which have not generally been implemented with AIDS, but have
been used historically with other diseases, include isolation and
quarantine.50 Some communities have invoked the public health
police power to limit the opportunities for high risk activities by
prohibiting the use of closed video booths in adult bookstores and
entertainment centers,61 and closing bathhouses and other locations
where there are opportunities for high risk sexual activity.62 More
recently, the question of whether there should be mandatory contact tracing andlor reporting of persons who test HIV positive has
been hotly debated in the wake of highly publicized allegations that

See id. at 56.
See Felicia R. Lee, Needle Exchange Programs Shown To Slow H.Z.V. Rates, N.Y.
~IMEs,
Nov. 26, 1994, at A4 (noting that intravenous drug users who are not involved in a
needle exchange program have a two percent to five percent higher rate of HIV infection
than those in a needle exchange program).
48 See Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco to Protect Children and Adolescents, 21 C.F.R. 8 897.2 (1996) (noting the purpose of
the regulation is to prohibit the sale of nicotine cigarettes and smokeless tobacco products to
children).
49 See Geraldine A. Collier, Battling Diabetes, the Silent Killer, TELEGRAM
& GAZETTE
(Worcester, Mass.), Jan. 20, 1997, at C l (discussing the need for intensive intervention
andlor medication to decrease the risk of diabetes); Kamilla Kuroda McClelland, New Baseline Formed for Diabetes: High-Risk; Nikkei Are More at Risk than Japanese in Japan, N.
AM. POST,June 27, 1997, at 1(encouraging Japanese-Americans to be screened earlier and
more often to catch and treat the disease earlier).
60 See Jew Ho v. Williamson, 103 F. 10,26 (N.D. Cal. 1900) (noting the quarantine of San
Francisco's Chinatown, because of an ostensible outbreak of bubonic plague, was invalid under the Fourteenth Amendment); Kirk v. Wyman, 65 S.E. 387, 388 (S.C. 1909) (upholding a
lower court's grant of a preliminary injunction to restrain the removal of a woman with leprosy to the city "pesthousen because of the asserted contagious nature of her disease). Cuba
is the only nation to seriously attempt isolation of all HIV-positive patients achieving a very
low rate of HlV infection, but Cuba abandoned its isolation program due to its high costs.
See Juanita Darling, New Day for AIDS Policy in Cuba, L.A. TIMES,
July 24, 1997, at B2
(discussing the Cuban government's approach to AIDS infected people).
6 1 See Doe v. Minneapolis, 898 F.2d 612 (8th Cir. 1990).
See New York v. New St. Mark's Baths, 497 N.Y.S.2d 979 (Sup. Ct.), afd, 505 N.Y.S.2d
1015 (App. Div. 1986).
46

47
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a young man from New York City has been the source of a one man
AIDS epidemic in Jarnestown, a small town in upstate New York.53

11. LESSON #2: AIDS AS A CHRONICILLNESS AND ACCESSTO
HEALTHCARE
The most salient feature of the evolution of AIDS over the past
decade and a half is that it has become a chronic illness. Today,
cases involving HIV-positive individuals and persons with AIDS are
paradigms for the problems that many people with chronic diseases
face in receiving care. The issues of access arise in a variety of contexts, including the ability to secure primary health care, to receive
emergency medical treatment, to obtain quality specialist care, and
to receive innovative, and often expensive treatment.

A. Access to Primary Care
People who are HIV positive or who have AIDS, or are suffering
from diabetes, lupus, or hepatitis B, require primary medical and
dental care in addition to specialty healthcare. Frequently those
who have the HIV or AIDS disease find it difficult to find a provider
who will treat them. In Abbott v. Bragdon,54 an asymptomatic HIVpositive woman who sought routine dental treatment to fill a cavity
disclosed that she was HIV positive.55 The dentist, Dr. Bragdon, refused to treat her, except in a hospital setting, where the cost of
treatment would be greater.56 After declining this offer, Ms. Abbott
brought suit under the Americans with Disabilities Act of 199057
(ADA). The First Circuit Court of Appeals held that Ms. Abbott
was disabled within the meaning of the ADA because she was a
person with asymptomatic HIV who was limited in a major life activity, i.e., reproduction.58 The court held that the burden was
therefore shifted to Dr. Bragdon to show that he was not obligated
63 See Jane Gross, Trail of Arrests, H.Z.V. Fears and a Woman's Tale of love, N.Y.TIMES,
Oct. 29, 1997, at Al; Tom Precious, H N Proposals Call for Testing, Disclosure, BUFF.NEWS,
Dec. 18, 1997, at A16.
54 107 F.3d 934 (1st Cir.), cert. granted, 118 S. Ct. 554 (1997).
56 See id.
66 See id. at 937.
57 42 U.S.C. 5 12101 (1994).
68 See Abbott, 107 F.3d at 939, 941. A plaintiff suing under the ADA is required to prove
three things: (1) that the plaintiff has a physical or mental impairment; (2) that such impairment adversely affects a "major life activity"; and (3) that the limitation is significant.
See id. at 938-39.
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to treat her because she posed a direct threat to his health and
safety.59 Abbott marked the first time that a court held that asymptomatic HIV status alone was sufficient to qualify as a disability
under the ADA, and was also important in recognizing that physicians and dentists offices are places of public accommodation within
the protection of the ADA.60
Other commentators, including Professor Scott Burris, have
noted the significant difficulties that HIV-positive individuals and
persons with AIDS have in gaining access to routine dental care.61
Similar difficulties in obtaining routine primary care are faced by
persons with hearing impairments, blind persons who rely upon
guide dogs for assistance in gaining access to a physician's office,
and those whose mental impairments make them unpopular patients with primary care providers. G2

B. Access to Emergency Care
Individuals who are HIV positive or who suffer from AIDS have
often found it difficult to receive emergency medical care because of
the concern of hospitals and physicians, whether or not wellfounded, that the patient's illness is too complex to be readily
treated in an emergency room and that an AIDS patient, once admitted, may prove to be a costly admission.63 The practice of refusing admission to an uninsured or otherwise undesirable patient
59 See id. at 948 (finding the evidence offered to buttress his claim was "too speculative or
too tangential").
60 See id. at 939 (stating that both symptomatic and asymptomatic HIV-positive persons
are covered by the Act). The Supreme Court has granted certiorari in Abbott. See 118 S. Ct.
554 (1997). A decision in Abbott will likely have an impact on another key decision involving
an HIV-positive employee who was terminated. See Runnebaum v. Nationsbank of Md., 123
F.3d 156 (4th Cir. 1997). It is noteworthy, however, that Runnebaum arose in the context of
employment discrimination and the court found no evidence that the plaintiffs HIV positive
status limited him in his procreative functions, thereby offering a possible distinction from
Abbott. See id. at 169-70.
61 See Scott Burris, Dental Discrimination Against the HN-Infected: Empirical Data, Law
and Public Policy, 13 YALEJ . ON REG. 1, 4 (1996) (analyzing empirical studies on dentists'
attitudes toward patients with HIV and concluding that many dentists are uncomfortable
treating such patients).
6~ See Tugg v. Towey, 864 F. Supp. 1201, 1211 (S.D. Fla. 1994) (granting a preliminary
injunction under the ADA to deaf and hearing-impaired plaintiffs seeking mental health
counseling from therapists who used sign language, rather than relying on sign language
interpreters); Mayberry v. Von Valtier, 843 F. Supp. 1160 (E.D. Mich. 1994) (involving a deaf
patient whose physician no longer wanted to pay for an interpreter to be present during appointments).
63 See Howe v. Hull, 874 F. Supp. 779, 783 (N.D. Ohio 1991) (claiming that a patient was
transferred to another hospital because of his HIV status).
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is known colloquially as "patient dumping."64 It has been addressed
by some state courts which have found a common law duty to
treat,66 and, on the federal level, by the Emergency Medical Treatment and Active Labor Act66 (EMTALA),which requires that all patients who arrive a t a hospital emergency room shall receive an appropriate medical screening examination to determine if they are in
the midst of a medical emergency or active labor, and prohibits
their transfer in a medically unstable condition, unless the physician certifies in writing that the benefits of the transfer outweigh
its potential risks.67 The exemplary AIDS case is Howe v. Hu11.68
Fred Charon, a patient with AIDS, sought treatment a t the emergency room of a community hospital when he suffered a severe prescription drug reaction unrelated to his underlying AIDS condition.69
Charon was denied admission to the hospital and
transferred to a nearby academic medical center.70 Although the
transfer was ostensibly due to the treating physician's concern that
Charon was suffering from a complicated drug reaction, requiring
treatment a t the academic medical center, ample evidence suggested that the drug reaction was simple and readily treatable at
the community hospital, and that the transfer was motivated by
Charon's AIDS status.71 A suit followed, asserting claims under
state tort law for the infliction of emotional distress, the ADA, the
Federal Rehabilitation Act of 197372 and EMTALA. The defendantphysician and hospital were found liable for intentional infliction of
emotional distress, and violating the ADA and the Rehabilitation
Act, but the claims under EMTALA were rejected.73 Still, as an allegedly "dumped7'patient, Charon symbolizes the growing number
of Americans with socially disfavored chronic diseases who have difficulty gaining access to vitally necessary hospital emergency care.

a See id. at 784.
6s See Thompson v. Sun City Community Hosp., Inc., 688 P.2d 605 (Ariz. 1984) (involving
a hospitals transfer of an unstable patient to another hospital for surgery); Wilmington Gen.
Hosp, v. Manlove, 174 A.2d 135 (Del. 1961) (involving a hospital transfer of an infant in a
potentially emergent situation, who later died due to a lack of care).
66 42 U.S.C. J 1395dd (1994).
67 See id. J 1395dd(c)(l)(A)(i)-(iii).
66 874 F. Supp. 779 (N.D. Ohio 1994).
69 See id. at 783.
70 See id. at 783-84.
71 See id. at 786.
72 29 U.S.C. J 701 (1994).
73 See Howe, 874 F. Supp. at 791.
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C. Access to Specialty Care

HIV-positive individuals and AIDS patients exemplify the problems of many sufferers from chronic diseases who need specialized
medical care, but have difficulty in gaining access to it due to the
limited knowledge of their primary care providers. In some cases,
the primary care provider is not sufficiently knowledgeable to recognize the disease and provide the necessary care. People with
Sjogrens Syndrome, a disease of the autoimmune system that
causes a loss in moisture functions in the tear ducts and the salivary glands, leading to vision and oral hygiene problems, are often
undiagnosed because of a lack of awareness in the general medical
and dental communities.74 In other cases, the primary care provider lacks the knowledge to make an appropriate referral. This
was a common experience among HIV-positive and AIDS patients,
particularly in the early stages of the AIDS epidemic. At that time,
many physicians and AIDS activists believed that people living
with HIV and AIDS were not receiving sufficient referrals to specialists and subspecialists, which were desperately necessary because generalist physicians were frequently unqualified to deliver
care.75
A different concern in the debate about access to specialty care is
that patients suffering from a particular disease, such as AIDS,
may become isolated in special treatment units as the pariahs of
the patient community.
Today, this discussion about the
"ghettoization" of AIDS plays itself out in the controversy surrounding New York State Health Department regulations mandating HIV testing for all newborns, which require that infants and
their mothers diagnosed as HIV positive be referred to AIDS speciali~ts.~6Opponents of the regulations argue 'that all primary
health providers should be able to provide appropriate care for
AIDS patients, and that mandating specialty referrals may lead
again to the medical and social isolation of HIV-positive individuals
-

See Joyce Howard Price, Ailment Keeps Millions in Misery: Sjogren's Syndrome Goes
Undiagnosed for Most Sufferers,WASH.POST,Dec. 28,1997, at A2.
75 See New York City HMOs Not Ready To Serve HW-Positive Women, Children, Study
Says, Health Care Daily (BNA) (Oct. 13, 1995), available in LEXIS, BNA Library, Bnahlt
File.
76 See N.Y. COMP.
CODES
R. & REGS. tit. 10, 8 69-1.3 (1995)(mandating newborn testing);
Charles W . Henderson, Transmission Baby AIDS Testing Law Faces Legal Challenge, AIDS
WKLY.PLUS,July 28,1997, available in 1997 W L 11006861 (discussing both support and opposition to the mandatory newborn testing law).
74
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and AIDS patients.77 However, to the extent that there is any consensus in the HIV-positive and AIDS community, it is that people
living with AIDS and HIV, as with any chronic disease, need to
have their health care overseen by a practitioner with sufficient expertise to manage a complex treatment regimen, who is able to
make immediate and competent referrals should the disease progress beyond his or her capabilities to treat it.
For the increasing numbers of Americans with chronic diseases
who receive their health care through a managed care organization,
there is an additional concern: that the constraints of the
"gatekeeper" system, in which all care is "managed" by a primary
care practitioner, will lead to medically harmful delays in, and denials of, treatment. Whether the patient is identified as being HIV
positive, or diagnosed with diabetes or hepatitis, the need is for
immediate referral to an appropriate specialist, who can initiate effective treatment, including the appropriate drug therapy. With
HIV-positive individuals, as well as sufferers from other chronic
diseases, the concern is always that a delay in treatment may lead
to irreversible deterioration in the patient's condition.

D. Access to Experimental Treatment
HIV and AIDS are similar to many chronic diseases in which the
standard of care for medical and drug treatment is rapidly evolving,
leading to major gaps in access to quality health care. Three big
picture questions have emerged. First, can the process of experimentation be expedited, so that definitive results can be obtained
about the efficacy of a particular innovative treatment? Second,
how soon is it reasonable to expect success at an academic medical
center to be translated into a standard of treatment that is available to patients across the nation at an affordable price? Third,
should everyone have access to the new standard of care, regardless
of the type or amount of health care insurance they have?
In the early stages of the AIDS epidemic, the controversy over access centered around participation in randomized clinical trials for
experimental drug treatments.78 The FDA asserted that before a
drug could be approved and marketed, a new drug must go through
See Henderson, supra note 76.
See, e.g., Testing Testing: Clinical Trials Are an Essential-and Expensive-Part of Drug
Development, ECONOMIST,
Feb. 1,1997,available in 1997 W L 8136413 (noting the process for
drug development).
77

78
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a lengthy series of animal studies and human studies in order to be
certain that a drug was both safe and effective for its intended
use.79 Clinical trial guidelines required all testing to be conducted
via randomized clinical trials, meaning that one could not receive
an experimental drug, no matter how promising, without participating in a clinical trial, and even then, one would not be guaranteed the drug, since the essential nature of a clinical trial requires
that some persons be in the control gro~p.~O
Aggressive protests by
"Act Up" and other AIDS activist groups led the FDA to promulgate
"Fast Track," "Parallel Track," and other expedited access regulations, which have substantially decreased the time necessary to
gain FDA approval for new pharmaceutical treatments for all patients affected with "immediately life-threatening" or "serious" dise a ~ e s . 8Recently
~
enacted legislation codifying the FDA's regulatory
approaches is expected to shorten the drug and medical device approval process even more.82
Today, there is a significant drug arsenal available to combat
HIV and AIDS, yet access problems remain. Three protease inhibitors-saquinavir, ritonavir, and indinavir-have proven successful
in combination with nucleoside analogues in clinical trials and
clinical practice in interfering with the HIV virus' ability to replicate itself.83 Early data show that the use of these "combination
therapies" can halt the progression from HIV positive status to fullblown AIDS,-help prevent the opportunistic infections which ultimately cause death in AIDS patients, and generally improve the
quality of life of HIV-positive and AIDS patients.84 Many patients
See id.
See, e.g., Stephen Fried, Cocktail Hour, WASH.POST,May 18, 1997, at W10 (discussing
the access problems arising from clinical guidelines).
81 See Sheila R. Shulman & Drusilla S. Raiford, FDA Regulations Provide Broader Access
to Unapproved Drugs, 30 J. CLIN.F'HIWUCOLQGY585, 585 (1990) (noting that the goal o f
new FDA procedures is to facilitate the availability of new medications, and obtain additional
data on their safety and efficacy);Lawrence M. Fisher, Hope Near the End of the Pipeline,
N.Y. TIMES, May 1, 1997, at Dl (discussing the introduction of new cancer treatments);Gina
Kolata, Interest Grows i n Licensing Shortcut for 2 AIDS Drugs, N.Y. TIMES, Sept. 25, 1990, at
C3 (noting the effectsof AIDS activists i n advancing the licensing process).
82 See Ronald Rosenberg, Biotech Firms Praise FDA Legislation: Bill Streamlines Drug
Approval Process, BOSTONGLOBE,Nov. 11, 1997, at D5 (discussing the favorable reception
given to the more streamlined approval process contained i n the FDA legislation).
83 See, e.g., Grace Brooke Huffman, Review of Protease Inhibitors for Use i n H N - 1 Infection, AM.FAM. PHYSICIAN,
June 1, 1997, available in 1997 W L 10150889 (analyzing the success of the protease inhibitors saquinavir, ritonavir, and indinavir).
84 See Lawrence 0.Gostin et al., National H N Case Reporting for the United States, 337
NEW ENG.J . MED. 1161,1162-63 (1997)(discussing the advances i n HIV treatment).
79

80

Heinonline - - 61 Alb. L. Rev. 1003 1997-1998

1004

Albany Law Review

Wol. 63

have experienced a substantial decrease in the "viral load" of HIV
in their bloodstream, a recognized biological marker for the advance
of HIV disease.85
However, these potent drugs are not available to everyone. The
primary barrier is financial. It costs $10,000 to $15,000 annually
just for the drugs for the combination therapy "cocktail," and many
HIV-positive and AIDS patients require other drugs as we11.86 Recent data show that this is money well spent, because increased
costs for drug therapy are offset by declines in the number of inpatient hospital admissions and the length of those stays as well.87
However, private and government insurers have been reluctant to
incur the up-front costs of combination therapy treatment, illustrating some of the inherent weaknesses of our multi-payer, fragmented health care system, in which different types of health care
needs are treated differently.88
Many insurers and managed care organizations place annual
caps on each patient's drug expenses, leaving patients with AIDS
and HIV, as well as sufferers from other chronic diseases, with the
sole option of paying for their necessary pharmaceuticals out of
pocket if they want to stay healthy.89 In some managed care organizations, only a limited group of drugs is on the approved drug
formulary. If protease inhibitors and other AIDS treatment drugs
are not on the formulary, the patient is simply out of luck.
Because many HIVIAIDS patients lose their health insurance
when they become sick enough to lose their jobs, eventually many
patients turn to the government to pay for their health care. More
See id.
See Diane Targovnik, Success of New AIDS Drugs Imperils Tax-Funded Program:
Pharmaceutical "Cocktail"So Costly that State-Federal Assistance Plan Going Broke, NEWS
TRJB.(Tacoma, Wash.), Jan. 26, 1997, a t A5 (noting that the cost of HlV drugs makes them
out of reach of some persons).
87 See Joan Stephenson, Paying Now for Costly AIDS Drugs May Save Money Later
(visited Feb. 8, 1998) <http://www.ama-assn.org/special/hiv/newsline/conferedretrocodjs0126,htm> (arguing that the decline in hospitalizations justifies the costs of protease inhibitors).
88 See Charles W Henderson, Quality of Life: AIDS Patients Living Langer While Money
Problem Grows, AIDS WKLY.PLUS,
July 28, 1997, available in 1997 WL 11006856 (observing
that hospitals and outpatient AIDS clinics are receiving less reimbursement from private
insurance companies); How Each State Is Faring with Demand for New IZZV Drugs, AIDS
Pol'y & L. (BNA)1,5 (Oct. 4, 1996) (noting that 22 states are expected to limit access to protease inhibitors, due to rising costs).
8s See, e.g., Managed Care Executives Cite Drug Costs as a Barrier to Profits, MANAGED
CAREOUTLOOK,
Aug. 8, 1997, available in 1997 WL 8469939 (observing that HMOs pursuing
short term budget goals are having problems with the rising costs of medications).
85

86
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than 100,000 AIDS patients receive a t least some of their drugs
through Medicaid.90 Under Title I1 of the Ryan White Care Act,gl
AIDS Drug Assistance Programs (ADAPs) are established in each
state to assist indigent patients in paying for necessary drugs.g2
Under this federal-state partnership, each state seeks approval for
its own ADAP program, choosing to cover those drugs which it believes it can afford.93 This has led to wide variations in each state
in the number of patients served and the particular drugs available.
For example, New York State's program, which serves more than
10,000 patients, is one of the most generous in the nation, which is
perhaps to be expected given the state's significant AIDS population, and the political clout of AIDS advocacy groups.94 Many other
states do not provide coverage for protease inhibitors, the most effective and expensive of the anti-HlV drugs, underscoring that a
person's access to effective health care can depend significantly on
the accident of geography.95 In addition, a significant limitation of
all ADAP programs, and of Medicaid in general, is that they cover
only persons who have been diagnosed with AIDS, rather than the
larger group of those who have tested HW positive, perhaps reflecting a political decision that the AIDSHIV dividing line is a n
appropriate way to apportion scarce government resources.96
However, this decision is unsound both medically and fiscally.
Protease inhibitors and other advanced anti-AIDS drugs are a significant breakthrough precisely because they can prevent the advance of HlV disease to AIDS, thus providing a cost-effective means
of limiting the spread of AIDS and the concomitant costs of AIDS
treatment. Viewing the ADAP program as a separate "pot" of

90 See Deborah L. Shelton, Rising Hopes-Rising
Costs (visited Feb. 8, 1998)
~http~I~~~.ama-assn.org/speciafiiv/newsinsciaamnews-/amnO916.htm>
(stating that
as many as 50,000 additional HIV-infected patients are likely to seek prescription drugs
through Medicaid).
91 See 42 U.S.C. $ 30OfF (1994) (establishing the framework for federal assistance to be
made available to states to provide services for HIV-positive individuals and their families).
82 See id.
93 See id. $ 300-ff-22 (describinghow states may use the federal grants).
94 See David Brown, AIDS Toll Falls by Half in New York; Health Ofiials Say New
Funds, Drugs May Drive Trend, WASH.
POST,Jan. 25, 1997, at A1 (discussing the positive
impact of the New York State ADAP, particularly in New York City).
96 See Study Details Limited Reach of ADAPs Despite Funding Jump, MED.& HEALTH,
July 14, 1997, available in 1997 WL 8689240 (noting that Arkansas, Nevada, Oregon, and
South Dakota do not cover the approved inhibitors).
96 See AIDS Lobbies Push for Expanded Care Coverage, AIDS ALERT,Jan. 1, 1998, at 6
(noting the legislatively imposed dichotomy between AIDS and HIV).
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money, to fund AIDS treatment rather than AIDS prevention, will
ultimately prove extremely short-sighted.

E. Denial of Access Due to Noncompliance
One of the most poignant ways in which AIDS patients both experience and symbolize the problems of patients with chronic illnesses is in compliance. While compliance means different things
in different disease contexts, it generally refers to the ability and
willingness of a patient to adhere to the treatment plan developed
by the physician, including refraining from medically injurious behavior and taking prescription drugs a t intervals that will maximize their efficacy. For an obese patient with high blood pressure
and cardiovascular disease, compliance means quitting smoking,
changing eating habits, taking medication to lower blood pressure,
and learning to exercise in moderation. For a patient who is diabetic, it means eating appropriate meals on a regular basis, monitoring blood glucose levels regularly, and taking oral or injectable
insulin a t prescribed levels. For an HIV-positive or AIDS patient,
compliance requires adhering to a strictly-timed regimen of taking
as many as twenty pills a day, some on an empty stomach and some
after a meal, as well as meeting the requirements for good health in
everyone: eating nutritious meals, getting a good night's sleep in a
safe place, and refraining from use of alcohol and other drugs. The
latter requirements may be difficult to meet for many HIV-positive
and AIDS patients, who may be homeless, poor, and using drugs.
With the advent of combination drug therapies, compliance for
patients with HIV and AIDS has become particularly complex.97
On the one hand, these new pharmaceutical interventions promise
significant remission in disease symptoms for many individuals,
allowing them to return to work and to their normal lives. On the
other, preliminary data make clear that even occasional lapses in
compliance may nullify the efficacy of these drugs in halting the onslaught of AIDS, when patients develop a drug-resistant strain of
the HIV virus.98 Even more troubling, if the noncompliant patient
97 See generally Sontag & Richardson, supra note 1, at A1 (discussing the "minefield of
ethical, legal rind public health concerns" and how strict compliance is necessary with combination drug therapies or else the virus may become resistant to treatment).
9s See DAVID
A. MORTON111, MEDICAL
PROOF OF SOCW SECURITYDISABILITY 2.15
(Supp. 1996) (stating that noncompliance by persons with tuberculosis has resulted in the
development of drug-resistant strains of the disease and that poor compliance by persons
with AIDS may have the same effect); see also Jennifer L. Rosato, The Ultimate Test of
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transmits this new version of the virus to others, through sexual
contact or intravenous drug use, the new virus can spread widely
throughout the population.
Thus, practitioners caring for an HIV or AIDS patient have competing obligations, to the patient and the community, in deciding
whether to prescribe a regimen of combination therapies to a patient whom they suspect may have compliance difficulties. First,
can the patient's compliance be predicted? Studies of AIDS and
other diseases suggest that physicians are poor predictors of compliance, and that it is important to disregard stereotypes based on
race, gender, social class, or drug use.99 Second, in light of the expense of combination therapies and the potential for the patient to
develop drug-resistance, it is critical that the practitioner spend
ample time discussing possible pitfalls with the patient and consider delaying, for a short while, the implementation of drug therapy, because the patient has only one chance to make it work.100
Broader public health concerns are even more difficult to resolve.
The lessons of dealing with non-compliant patients with active,
drug-resistant tuberculosis (TB) may be useful, although they are
not strictly parallel. With active TB, it is possible to mandate a
short course (twice a week for two to four weeks) of directly observed therapy to ensure that a patient is taking the medication
and thus eliminate the risk of transmission of active, drug-resistant
TB.101 With AIDS and HIV, the requirement of combination therapy is expected to be indefinite, and the patient monitoring required to ensure compliance around the clock impracticable. The
incredible success of combination therapy itself may provide the
necessary "carrot" to encourage compliance, as patients who feel
healthier are much more likely to continue treatment. In this view,
it would be beneficent parentalism at its worst to prejudge the
likely outcome for a particular patient who could be given the op-

Autonomy: Should Minors Have a Right to Make Decisions Regarding Life Sustaining
Treatment?, 49 RUTGERSL. REV. 1,61 n.265 (1996)(noting that drug resistant strains of HIV
may result from poor compliance).
99 See Clinicians Explore Ways To Ensure Compliance: More Counseling Needed, AIDS
ALERT,Feb. 1,1997, available i n 1997 W L 8961919 (suggesting that physicians should design
a medication schedule tailored to a patient's lifestyle).
100 See MORTON,
supra note 98, 4 2.15 (stating that physicians should provide patients
with suggestions for remembering medication regimens as well as maintain contact with the
patient to monitor compliance); Sontag & Richardson, supra note 1, at A1 (noting the dilemmas physicians face when deciding whether to treat patients with combination drugs).
101 See Newark v. J.S., 652 A.2d 265, 269 (N.J. Super. Ct. 1993) (stating that noncompliance may lead to relapse and development of a drug resistant strain of tuberculosis).
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portunity to try protease inhibitors. Thus, all patients must be
given a chance to benefit from the new therapies, as well as the
support system necessary to make a chance worth taking.

F. Denial of Access Because of Lack of Insurance: The Limitations
of an Employment-Linked Health Care System
The evolution of AIDS over the last fifteen years is a lens through
which to examine the strengths and weaknesses of the American
health care system. The most significant weakness is that for people under 65 health care coverage is tied closely to employment
status.102 It is largely an historical accident that health insurance
coverage became employment-based, due to World War I1 price controllers who determined to exempt employee benefits from wage
and price controls.103 Today, as more Americans are aging out of
the ranks of the employed, and many Americans are working parttime, or a t low wage jobs that do not provide health insurance benefits, the wisdom of this decision is being reexamined.104 In the case
of people with HIV and AIDS, as with many other chronic diseases,
most people try to work until they are too sick to continue, often
seeking reasonable accommodation in employment tasks along the
way. One of the most significant barriers to adequate health care is
the trend of employers to self-insure for the health care needs of
their employees rather than purchase insurance on their employees'
behalf.105 Under ERISA, self-insured employee benefit plans are
not subject to state laws whose purpose is to guarantee minimum
access standards to workers and their dependents.106 Thus, employers are free to impose disease specific caps on coverage, or re-

102 In 1996,64%of Americans were covered by employmentbased health insurance. See
FRONSTIN,
supra note 28, at 3-4.
10s See Dayna Bowen Matthew, Controlling the Reverse Agency Costs of EmploymentBased Health Insurance: Of Markets, Courts, and a Regulatory Quagmire, 31 WAKEFOREST
L. REV. 1037,1041-42 (1996).
104 Indeed, President Clinton's proposal to expand Medicare to include people aged 55-64
reflects this new economic reality. See Robert Pear, Clinton Plan To Widen Medicare Can't
Jan. 20, 1998, at A1 (critiquing a plan that would alPay for Itself; Experts Say, N.Y. TIMES,
low persons under 65 to buy full Medicare coverage).
105 See Thomas E. Bartnun, Fear, Discrimination and Dying in the Workplace: AlDS and
the Capping of Employees' Health Insurance Benefits, 82 KY. L.J. 249, 253-54 (1994)
(explaining that such a tactic allows employers to cut administrative costs while circumventing state insurance laws).
106 See 29 U.S.C. 55 1001-1461 (1994).
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quire greater co-payments for certain illnesses than others.lo7 The
question of whether an insurer's decision to discriminate against
individuals with certain types of illnesses in its underwriting violates the ADA is a complex issue that has received little attention
from the courts until recently. In Parker v. Metropolitan Life Insurance Co.,l08 the Sixth Circuit Court of Appeals held, over a
strong dissent, that the distinction between mental and physical
illness in the length of coverage provided by an employer purchased
disability policy did not violate Title I11 of the ADA.109 The Court
found that the ADA was not violated because Title I11 (governing
places of public accommodation) applies only to physical structures,
and thus the ADA does not govern insurance policies which were
purchased by the employer for the benefit of its employees, as opposed to an individual entering into an insurance company's office.110 The Court further reasoned that providing disability policies
with different benefits depending on the nature of the disability did
not run afoul of the ADA because the ADA was denied to remedy
discrimination between the disabled and the non-disabled, and not
discrimination between individuals with different disabilities.111
Thus, it would appear under the Parker court's reasoning, that a
self-insured employer could distinguish among diseases, insuring
HIV and AIDS, in the amount of health care coverage it provided.
Another court has held that where an employer purchased health
insurance from a company that refused to offer aG insurance to an
employee with AIDS, the ADA was violated.112 It-is as yet unclear
what the impact of HIPAA will be on the question of permissible
discrimination on the basis of HIV positive or AIDS status, as the
avowed purpose of HIPAA was to ensure that people should not be
denied insurance coverage due to a preexisting condition.113 How107 See McGann v. H & H Music Co., 946 F.2d 401 (5th Cir. 1991) (affirming summary
judgment for an employer who changed health plans to reduce maximumbenefits for employees suffering from AIDS from $1million to $5000, holding that such actions are not prohibited by ERISA).
108 121 F.3d 1006 (6th Cir. 1997).
109 See i
d.at 1015 (stating "[tlhe disparity in benefits provided in the policy at issue is also
not prohibited by the ADA because the ADA does not mandate equality between individuals
with different disabiliti'esn).
110 See id..at 1011 n.3.
111 See id. at 1015.
112 See Anderson v. Gus Mayer Boston Store, 924 F. Supp. 763, 781 (E.D. Tex. 1996)
(holding that choosing an insurer that would never cover an employee because of his disability denied the employee equal access to insurance, thus discriminating against him).
11s See Eric Mills Holmes, Solving the ZnsurancelGenetic Fair1 Unfair Discrimination Dilemma in Light of the Human Genome Project, 85 KY. L.J.503, 657-58 (1997) (stating that a
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ever, in Parker the court rejected this argument. It reasoned first
that the enactment of the Mental Health Parity Act of 1996 as an
amendment to HIPAA reflected congressional understanding that
the ADA did not apply to insurance policies.114 second, it concluded
that the limitation of the Mental Health Parity Act to health insurance (as opposed to disability) policies demonstrated a collective
congressional belief that there was not a strong need to provide
parity between mental and physical disabilities in this realm of insurance coverage or in the realm of disability insurance coverage. 115
Once employees become too disabled to work, many will try to exercise their options under the Consolidated Omnibus Budget Reconciliation Act of 1985 (COBRA)116to continue their work-based insurance coverage for the eighteen month maximum period, and
then seek coverage under the employer's disability insurance plan.
Ultimately, persons with HIV/AIDS and other chronic diseases are
likely to seek government assistance through Medicaid, spending
themselves into poverty in order to qualify. However, current
Medicaid eligibility criteria limit coverage to persons who have fullblown AIDS, excluding persons who are HIV-positive.117 Many
AIDS advocates have questioned the wisdom of these criteria arguing that the need for health care services is equally great a t the
moment of initial HIV diagnosis, because many prophylactic strategies are most successful then, and will thus decrease the costs of
AIDS treatment overall.ll8

AIDS has come of age in the 1990s. It has undergone a dramatic
metamorphosis from a little understood, often unspeakable, and
rare disease, affecting a relatively small number of people who were
already socially stigmatized. AIDS is now a mainstream disease,
affecting people across the nation, from all segments of society,
"goal of the Act is to improve portability and continuity of an employee's group health insurance coverage under ERISA when an employee . . . with a pre-existing condition changes employers").
"4 See Parker, 121 F.3d at 1018.
116 See id.
116 29 U.S.C. $ 1161 (1994).
117 See Isbell, supra note 24, at 32 (noting that most HIV-infected adults obtain Medicaid
through supplemental security income, requiring a physician's diagnosis of full-blown AIDS
to meet disability regulations).
118 See id. at 33 (discussing a study estimating that 60%of people infected with HIV could
benefit from early intewention).
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even as its sufferers are primarily the poor and persons of color,
who are most likely to have difficulty in gaining access to quality
health care.
Because of the recent dramatic advances in the clinical treatment
of AIDS, and the potential of forestalling many cases from advancing from HIV to AIDS, people with AIDS are now living with a
chronic disease. AIDS, like all chronic diseases, needs medical
management that is continuing, aggressive, expensive, and complex. The problems faced by persons with HIV and AIDS are the
same as those confronted by other Americans with chronic diseases,
despite the media attention that AIDS has received which has often
made AIDS appear sui generis, a disease unto itself. As we near
the close of the twentieth century, it is worth reflecting on the lessons we have learned from the AIDS epidemic, to consider how we
might transform the American health care system to serve the
needs of all its citizens-the healthy, the chronically ill, and the
acutely ill and injured.

Heinonline - - 61 Alb. L. Rev. 1011 1997-1998

